The bioprinting method is faster and more reliable than previous methods, with the ability to create about 200 mini kidneys in 10 minutes without compromising quality.
Interim Phase 3 trial data shows that the vaccine candidate AZD1222 is effective at preventing COVID-19 and offers a high level of protection.
Pfizer and BioNTech have completed the final efficacy analysis in the ongoing Phase 3 study of their mRNA-based COVID-19 vaccine candidate, BNT162b2.
Interim analysis of Moderna's Phase 3 study of mRNA-1273 finds that the COVID-19 vaccine candidate has an efficacy of 94.5% and remains stable at -20°C for up to six months.
ClearMate allows a patient to hyperventilate off the alcohol in their system while returning precisely the amount of carbon dioxide to the body to keep it at normal levels in the blood.
Hot on the heels of Pfizer and BioNTech's SARS-CoV-2 vaccine candidate, Russia's Sputnik V has demonstrated high efficacy of 92%.
Pfizer and BioNTech say their SARS-CoV-2 vaccine candidate has proved more than 90% effective in preventing COVID-19 in participants without prior evidence of infection.
The Australian Government has secured 50 million more doses of COVID-19 vaccines, as a result of new agreements with Novavax and Pfizer/BioNTech.
A novel agent that targets a mutated form of the KRAS gene — the most commonly altered oncogene in human cancers — shrank tumours in most patients in a clinical trial.
Dexamethasone can boost survival of premature babies when given to pregnant women at risk of preterm birth in low-resource settings.
A new anticancer drug candidate offers a way to inhibit both tumour growth and drug-induced hyperglycaemia in multiple models of HR+ breast cancer.
Interim results indicate that the four treatments tested appear to have little or no effect on 28-day mortality or the in-hospital course of COVID-19 among hospitalised patients.
Scientists have developed a pill which uses the stomach as a drug reservoir and delivers medicines slowly over time to patients with Parkinson's disease.
Metformin could be particularly beneficial for people with type 2 diabetes who are older or looking to become pregnant, as discovered by two separate studies.
The TGA has registered Novartis's LUXTURNA, the first gene therapy in Australia, for the treatment of patients with inherited retinal dystrophy.